Because of its strong association with liver-related morbidity and premature death, fibrosis has become the principal focus in secondary care. This is particularly true in patients with non-alcoholic fatty liver disease (NAFLD) which accounts for approximately 25% of all liver diseases.

  • In the case of primary liver tumours (PLT), some molecular targets for precision medicine have been identified. In particular, immune checkpoint inhibitor-based treatments have shown promising results. To refine treatment selection and promote the combination of systemic and loco-regional therapeutic approaches (such as new types of tumour embolization, direct injections into the tumour and innovative radiotherapy), new immune prognostic signatures of efficacy and toxicity need to be defined.
  • In the context of end-stage liver disease, bacterial infection is one of the most important causes of acute decompensation and death. It is of crucial importance to obtain a better knowledge of bacterial resistance in severely ill patients.
  • Despite the considerable efforts that have been devoted to the development of orphan drugs, many genetic and rare liver diseases (GARLDs) still lack effective cures and call for new therapies. Since a majority of GARLDs stem from genetic disorders, recent progress in tailor-made pharmacological and gene therapies could offer more options to treat them.
The goals

Pathological processes in the extracellular compartment and endothelium of patients with liver diseases.
Hépatinov intends to:


identify at an early stage of NALFD the set of proteins from the hepatic extracellular compartment that are sensitive to oxidative modifications;

Chronic liver injury is characterised by the deposition of extracellular matrix in response to persistent liver damage. Although oxidative stress is recognised as the second hit which leads from steatosis to NASH and fibrosis reactive oxygen species within the extracellular compartment have been little described and their importance for disease progression is totally unexplored. As all proteins are not equally sensitive to oxidation, Hépatinov will identify which proteins are oxidised at various levels of stress and analyse their ability to induce disease progression.

identify the in vitro and in vivo toxic effects on endothelial cells in patients with NAFLD;

Vascular endothelial dysfunction seems to be an early event in NAFLD and may be implicated in both liver injury progression and systemic atherosclerosis. This hypothesis will be studied by assessing the association between pre - and postprandial circulating lipid profiles and vascular endothelial dysfunction in a population of NAFLD patients.

assess the quality of collagen fibres inliver fibrosis during the different stages of chronic liver disorders;

Second-harmonic generation and synchrotron deep-ultraviolet microscopies allow for the qualitative evaluation of fibrosis by identifying individual collagen fibrils and quantifying their physical properties. Diagnosis and prognosis will be established by assessing the quality of collagen fibres in a cohort of patients displaying different degrees of fibrosis (F0-F4) in the context of different aetiologies (NAFLD, alcoholic liver disease and liver disease after the cure of HCV).

Identification of signatures for the development of a rationale and risk evaluation of immunotherapy in patients with primary liver tumours (PLT).

The development of drugs for PLT has been characterised by numerous failures and a comprehensive biomarker analysis has not yet been reported notably in the case of cholangio carcinoma (CC). Hépatinov will improve the efficacy and safety of immunotherapy
  • by identifying new genomic/phenotypic tumour signatures,
  • by identifying the specific signatures of autoimmune serum and their dynamic changes during immunotherapy,
  • by identifying global serum immune response signatures against gut microbiota and their changes under immunotherapy (using imaging-based prognostic techniques, including combinations of morphological and functional imaging strategies - immunoTEP, tumour elastometry and vascular dynamic imaging) and
  • by propose new methods of manipulating the gut microbiome in order to extend immune checkpoint therapy to patients with a primary or a secondary resistance.

For data integration, Hépatinov will rely on regularised and sparse generalised canonical correlation analysis (RGCCA) which is a general framework for the joint analysis of multiple sources.

Innovative loco-regional and combined immunotherapy-based approaches for primary liver tumours.

Technological advances have improved the safety and effectiveness of tumour embolization and radiation therapy in the management of primary tumours. Combining these therapies could improve the survival of patients with CC. Although numerous studies have demonstrated that the presence of circulating tumour cells (CTCs) is significantly associated with the prognosis for primary liver tumours, new approaches such as the identification of tumour cell surface antigen and cancer-associated macrophage-like (CAML) cells are needed, particularly in the context of the innovative therapies described above.

Hépatinov will aim at
  • the evaluation of new agents for intravascular embolization;

i.e. radioembolization with HO-166, resorbable drug-loaded embolics, intra-tumour delivery of checkpoint inhibitors using intra-arterial, intra-hepatic or direct percutaneous administration, and the direct injection into the tumour of oncolytic viruses JX594-Transgene.

  • The evaluation of the immunomodulatory effects of chemo- and radio-embolization using these new agents and/or combined immune-based therapies;
  • study of 3D conformal radiotherapy and intensity-modulated radiotherapy (IMRT) in patients with CC;
  • study of factors influencing early recurrence.

Study of the in vivo evolution of bacterial resistance in patients with end-stage liver disorders.

Hépatinov will perform a comprehensive analysis of bacterial adaptations to the antibiotic protocols used to treat infected cirrhotic patients and ultimately to propose possible alternate therapies to bypass this bacterial resistance to antibiotics.

Development of tailor-made pharmacological therapies in genetic cholestasis.

Progressive familial intrahepatic cholestasis type 2 (PFIC2) and type 3 (PFIC3) are autosomal recessive types of hepatocellular cholestaseswhich manifest themselves usually during the first year of life and require liver transplantation in childhood.The need for alternative therapies is of crucial importance. Bile acid synthesis defects (BASD) are also severe childhood and genetic cholestasis disorders that benefit from cholic acid therapy. Data concerning the outcomes in adulthood of patients treated with cholic acid are deficient.

Development of gene therapy trials for genetic liver diseases.

Validation in pre-clinical models is required before gene therapy can be translated to humans. Hépatinov focuses on the following diseases:
  • glycogen storage diseases (GSD) using AAV vectors;
  • Crigler Najjar disease;
  • PFIC2 and PFIC3 using liver tropic AAV vectors.

Development of cell therapy for liver diseases.

The UCLouvain pediatric hepatology and cell therapy laboratory has a long history of hepatocyte and stem cell transplantation in inborn and acquired liver diseases. Discovery and in-depth investigations of anti-inflammatory and anti-fibrotic properties of a specific liver derived progenitor cell have led to develop their clinical use in fibro-inflammatory liver diseases.

Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis.
Efe C, Lammert C, Taşçılar K, Dhanasekaran R, Ebik B, Higuera-de la Tijera F, Calışkan AR, Peralta M, Gerussi A, Massoumi H, Catana AM, Purnak T, Rigamonti C, Aldana AJG, Khakoo N, Nazal L, Frager S, Demir N, Irak K, Melekoğlu-Ellik Z, Kacmaz H, Balaban Y, Atay K, Eren F, Alvares-da-Silva MR, Cristoferi L, Urzua Á, Eşkazan T, Magro B, Snijders R, Barutçu S, Lytvyak E, Zazueta GM, Demirezer-Bolat A, Aydın M, Heurgue-Berlot A, De Martin E, Ekin N, Yıldırım S, Yavuz A, Bıyık M, Narro GC, Kıyıcı M, Akyıldız M, Kahramanoğlu-Aksoy E, Vincent M, Carr RM, Günşar F, Reyes EC, Harputluoğlu M, Aloman C, Gatselis NK, Üstündağ Y, Brahm J, Vargas NCE, Güzelbulut F, Garcia SR, Aguirre J, Anders M, Ratusnu N, Hatemi I, Mendizabal M, Floreani A, Fagiuoli S, Silva M, Idilman R, Satapathy SK, Silveira M, Drenth JPH, Dalekos GN, N Assis D, Björnsson E, Boyer JL, Yoshida EM, Invernizzi P, Levy C, Montano-Loza AJ, Schiano TD, Ridruejo E, Wahlin S.
Liver Int. 2022 Mar;42(3):607-614. doi: 10.1111/liv.15121. Epub 2021 Dec 13. PMID: 34846800.
Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: Phase 2 study.
Baumann U, Sturm E, Lacaille F, Gonzalès E, Arnell H, Fischler B, Jørgensen MH, Thompson RJ, Mattsson JP, Ekelund M, Lindström E, Gillberg PG, Torfgård K, Soni PN.
Clin Res Hepatol Gastroenterol. 2021 Sep;45(5):101751. doi: 10.1016/j.clinre.2021.101751. Epub 2021 Jun 26. PMID: 34182185.
Impact of COVID - 19 in patients awaiting liver transplantation.
Kounis I, Duhaut L, Breard T, Samuel D, Coilly A.
Liver Int. 2022 Jan;42(1):256-257. doi: 10.1111/liv.15105. Epub 2021 Nov 29. PMID: 34797949; PMCID: PMC8661909.
Integrated Genomic Analysis Identifies Driver Genes and Cisplatin-Resistant Progenitor Phenotype in Pediatric Liver Cancer.
Hirsch TZ, Pilet J, Morcrette G, Roehrig A, Monteiro BJE, Molina L, Bayard Q, Trépo E, Meunier L, Caruso S, Renault V, Deleuze JF, Fresneau B, Chardot C, Gonzales E, Jacquemin E, Guerin F, Fabre M, Aerts I, Taque S, Laithier V, Branchereau S, Guettier C, Brugières L, Rebouissou S, Letouzé E, Zucman-Rossi J.
Cancer Discov. 2021 Oct;11(10):2524-2543. doi: 10.1158/2159-8290.CD-20-1809. Epub 2021 Apr 23. PMID: 33893148; PMCID: PMC8916021.(available on 2022-10-01)
Predictive factors for hepatocellular carcinoma in chronic hepatitis B using structural equation modeling: a prospective cohort study.
Lam L, Fontaine H, Bourliere M, Lusivika-Nzinga C, Dorival C, Thabut D, Zoulim F, Habersetzer F, Asselah T, Duclos-Vallee JC, Bronowicki JP, Mathurin P, Decaens T, Ganne N, Guyader D, Leroy V, Rosa I, De Ledinghen V, Cales P, Causse X, Larrey D, Chazouilleres O, Gelu-Simeon M, Loustaud-Ratti V, Metivier S, Alric L, Riachi G, Gournay J, Minello A, Tran A, Geist C, Abergel A, Raffi F, D'Alteroche L, Portal I, Lapidus N, Pol S, Carrat F; ANRS/AFEF Hepather study group.
Clin Res Hepatol Gastroenterol. 2021 Sep;45(5):101713. doi: 10.1016/j.clinre.2021.101713. Epub 2021 Apr 27. PMID: 33930591.

A Model for Early Endoscopic Detection of High-Risk Gastroesophageal Varices in Children With Biliary Atresia.
Ackermann O, de Boissieu P, Bernard O, Gonzalès E, Jacquemin E, Duché M.
J Pediatr Gastroenterol Nutr. 2021 Dec 28. doi: 10.1097/MPG.0000000000003375. Epub ahead of print. PMID: 34984987.
Adenosine kinase deficiency: Three new cases and diagnostic value of hypermethioninemia.
Becker PH, Demir Z, Mozer Glassberg Y, Sevin C, Habes D, Imbard A, Mussini C, Rozenfeld Bar Lev M, Davit-Spraul A, Benoist JF, Thérond P, Slama A, Jacquemin E, Gonzales E, Gaignard P.
Mol Genet Metab. 2021 Jan;132(1):38-43. doi: 10.1016/j.ymgme.2020.11.007. Epub 2020 Nov 28. PMID: 33309011.
Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis.
Petroff D, Blank V, Newsome PN, Shalimar, Voican CS, Thiele M, de Lédinghen V, Baumeler S, Chan WK, Perlemuter G, Cardoso AC, Aggarwal S, Sasso M, Eddowes PJ, Allison M, Tsochatzis E, Anstee QM, Sheridan D, Cobbold JF, Naveau S, Lupsor-Platon M, Mueller S, Krag A, Irles-Depe M, Semela D, Wong GL, Wong VW, Villela-Nogueira CA, Garg H, Chazouillères O, Wiegand J, Karlas T
Lancet Gastroenterol Hepatol. 2021 Mar;6(3):185-198. doi: 10.1016/S2468-1253(20)30357-5. Epub 2021 Jan 16. PMID: 33460567.
ATP7B variant spectrum in a French pediatric Wilson disease cohort
Eduardo Couchonnal, Sophie Bouchard, Thomas Damgaard Sandahl, Cecile Pagan, Laurence Lion-François, Olivier Guillaud, Dalila Habes, Dominique Debray, Thierry Lamireau, Pierre Broué, Alexandre Fabre, Claire Vanlemmens, Rodolphe Sobesky, Frederic Gottrand, Laure Bridoux-Henno, Abdelouahed Belmali, Aurelia Poujois, Anne Sophie Brunet, Alain Lachaux, Muriel Bost
Eur J Med Genet. 2021 Oct;64(10):104305. doi: 10.1016/j.ejmg.2021.104305. Epub 2021 Aug 13. Erratum in: Eur J Med Genet. 2021 Sep 17;:104341. PMID: 34400371.
Blood microbiota and metabolomic signature of major depression before and after antidepressant treatment: a prospective case-control study.
Dragos Ciocan, Anne-Marie Cassard, Laurent Becquemont, Céline Verstuyft, Cosmin Sebastian Voican, Khalil El Asmar, Romain Colle, Denis David, Séverine Trabado, Bruno Feve, Philippe Chanson, Gabriel Perlemuter, Emmanuelle Corruble.
J Psychiatry Neurosci. 2021 May 19;46(3):E358-E368, PMID: 34008933, DOI: 10.1503/jpn.200159
Cardiovascular disorders in patients with congenital portosystemic shunts: 23 years of experience in a tertiary referral centre.
Lambert V, Ladarre D, Fortas F, Durand P, Hervé P, Gonzales E, Guérin F, Savale L, McLin VA, Ackermann O, Franchi-Abella S; International Registry of Congenital Portosystemic Shunts (IRCPSS).
Arch Cardiovasc Dis. 2021 Mar;114(3):221-231. doi: 10.1016/j.acvd.2020.10.003. Epub 2020 Dec 3. PMID: 33281106
Changing Trends in Liver Transplantation: Challenges and Solutions.
Ivanics T, Abreu P, De Martin E, Sapisochin G.
Transplantation. 2021 Apr 1;105(4):743-756. doi: 10.1097/TP.0000000000003454. PMID: 32910093.
Congenital portosystemic shunts: Vascular liver diseases: Position papers from the francophone network for vascular liver diseases, the French Association for the Study of the Liver (AFEF), and ERN-rare liver.
Guérin F, Franchi Abella S, McLin V, Ackermann O, Girard M, Cervoni JP, Savale L, Hernandez-Gea V, Valla D, Hillaire S, Dutheil D, Bureau C, Gonzales E, Plessier A.
Clin Res Hepatol Gastroenterol. 2020 Sep;44(4):452-459. doi: 10.1016/j.clinre.2020.03.004. Epub 2020 Apr 9. PMID: 32279979.
Donor HLA Class 1 Evolutionary Divergence Is a Major Predictor of Liver Allograft Rejection : A Retrospective Cohort Study.
Féray C, Taupin JL, Sebagh M, Allain V, Demir Z, Allard MA, Desterke C, Coilly A, Saliba F, Vibert E, Azoulay D, Guettier C, Chatton A, Debray D, Caillat-Zucman S, Samuel D.
Ann Intern Med. 2021 Aug 24. doi: 10.7326/M20-7957. Epub ahead of print. PMID: 34424731.
Early liver transplantation for corticosteroid non-responders with acute severe autoimmune hepatitis: The SURFASA score.
De Martin E, Coilly A, Chazouillères O, Roux O, Peron JM, Houssel-Debry P, Artru F, Silvain C, Ollivier-Hourmand I, Duvoux C, Heurgue A, Barge S, Ganne-Carrié N, Pageaux GP, Besch C, Bourlière M, Fontaine H, de Ledinghen V, Dumortier J, Conti F, Radenne S, Debette-Gratien M, Goria O, Durand F, Potier P, Di Martino V, Reboux N, Ichai P, Sebagh M, Mathurin P, Agostini H, Samuel D, Duclos-Vallée JC
FILFOIE consortium – France.
J Hepatol. 2021 Jun;74(6):1325-1334. doi: 10.1016/j.jhep.2020.12.033. Epub 2021 Jan 24. PMID: 33503489.
Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: Phase 2 study.
Baumann U, Sturm E, Lacaille F, Gonzalès E, Arnell H, Fischler B, Jørgensen MH, Thompson RJ, Mattsson JP, Ekelund M, Lindström E, Gillberg PG, Torfgård K, Soni PN.
Clin Res Hepatol Gastroenterol. 2021 Jun 25:101751. doi: 10.1016/j.clinre.2021.101751. PMID: 34182185.
Endoscopic Retrograde Cholangiopancreatography in Infants: Availability Under Threat: A Survey on Availability, Need, and Clinical Practice in Europe and Israel.
Koot BGP, Kelly DA, Hadzic N, Gonzales E, Hierro L, Davenport M, Keil R, Fockens P, Baumann U.
J Pediatr Gastroenterol Nutr. 2020 Aug;71(2):e54-e58. doi: 10.1097/MPG.0000000000002752. PMID: 32304552.
External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV.
Poynard T, Lacombe JM, Deckmyn O, Peta V, Akhavan S, de Ledinghen V, Zoulim F, Samuel D, Mathurin P, Ratziu V, Thabut D, Housset C, Fontaine H, Pol S, Carrat F.
JHEP Rep. 2021 Apr 24;3(4):100298. doi: 10.1016/j.jhepr.2021.100298. PMID: 34142073; PMCID: PMC8187244.
Functional rescue of an ABCB11 mutant by ivacaftor: A new targeted pharmacotherapy approach in bile salt export pump deficiency.
Mareux E, Lapalus M, Amzal R, Almes M, Aït-Slimane T, Delaunay JL, Adnot P, Collado-Hilly M, Davit-Spraul A, Falguières T, Callebaut I, Gonzales E, Jacquemin E.
Liver Int. 2020 Aug;40(8):1917-1925. doi: 10.1111/liv.14518. Epub 2020 Jun 8. PMID: 32433800.
Galaxy Is a Suitable Bioinformatics Platform for the Molecular Diagnosis of Human Genetic Disorders Using High-Throughput Sequencing Data Analysis. Five Years of Experience in a Clinical Laboratory.
Chappell K, Francou B, Habib C, Huby T, Leoni M, Cottin A, Nadal F, Adnet E, Paoli E, Oliveira C, Verstuyft C, Davit-Spraul A, Gaignard P, Lebigot E, Duclos-Vallee JC, Young J, Kamenicky P, Adams D, Echaniz-Laguna A, Gonzales E, Bouvattier C, Linglart A, Picard V, Bergoin E, Jacquemin E, Guiochon-Mantel A, Proust A, Bouligand J.
Clin Chem. 2021 Dec 6:hvab220. doi: 10.1093/clinchem/hvab220. Epub ahead of print. PMID: 34871369.
Glycerol Phenylbutyrate Therapy in Progressive Familial Intrahepatic Cholestasis Type 2.
Almes M, Jobert A, Lapalus M, Mareux E, Gonzales E, Jacquemin E.
J Pediatr Gastroenterol Nutr. 2020 Jun;70(6):e139-e140. doi: 10.1097/MPG.0000000000002713. PMID: 32443059.
HCV Cure and Cannabis Abstinence Facilitate Tobacco Smoking Quit Attempts in HIV-HCV Co-Infected Patients (ANRS CO13 HEPAVIH Cohort Study).
Barré T, Mercié P, Marcellin F, Esterle L, Duvivier C, Teicher E, Bureau M, Chas J, Salmon-Céron D, Sogni P, Carrieri MP, Wittkop L, Protopopescu C; ANRS CO13 HEPAVIH Study Group.
AIDS Behav. 2021 Apr 27. doi: 10.1007/s10461-021-03277-x. Online ahead of print. PMID: 33903998
In vitro functional rescue by ivacaftor of an ABCB11 variant involved in PFIC2 and intrahepatic cholestasis of pregnancy.
Mareux E, Lapalus M, Ben-Saad A, Callebaut I, Falguières T, Gonzales E, Jacquemin E
Orphanet J Rare Dis. 2021 Nov 18;16(1):484. doi: 10.1186/s13023-021-02125-4. PMID: 34794484; PMCID: PMC8600881
Long term results of liver transplantation for alpha-1 antitrypsin deficiency.
Guillaud O, Jacquemin E, Couchonnal E, Vanlemmens C, Francoz C, Chouik Y, Conti F, Duvoux C, Hilleret MN, Kamar N, Houssel-Debry P, Neau-Cransac M, Pageaux GP, Gonzales E, Ackermann O, Gugenheim J, Lachaux A, Ruiz M, Radenne S, Debray D, Lacaille F, McLin V, Duclos-Vallée JC, Samuel D, Coilly A, Dumortier J.
Dig Liver Dis. 2021 May;53(5):606-611. doi: 10.1016/j.dld.2020.10.016. Epub 2020 Nov 1. PMID: 33139195.
Long-term results of pediatric liver transplantation for autoimmune liver disease.
Couchonnal E, Jacquemin E, Lachaux A, Ackermann O, Gonzales E , Lacaille F, Debray D, Boillot O, Guillaud O, Wildhaber BE, Chouik Y, McLin V, Dumortier J.
Clin Res Hepatol Gastroenterol. 2021 May;45(3):101537. doi: 10.1016/j.clinre.2020.08.013. Epub 2020 Oct 17. PMID: 33077391.
Molecular Regulation of Canalicular ABC Transporters.
Amel Ben Saad, Alix Bruneau, Elodie Mareux, Martine Lapalus, Jean-Louis Delaunay, Emmanuel Gonzales, Emmanuel Jacquemin, Tounsia Aït-Slimane, Thomas Falguières.
Review Int J Mol Sci. 2021 Feb 20;22(4):2113. doi: 10.3390/ijms22042113. PMID: 33672718.
Multikinase inhibitor-induced liver injury in patients with cancer: A review for clinicians.
Houron C, Danielou M, Mir O, Fromenty B, Perlemuter G, Voican CS.
Crit Rev Oncol Hematol. 2021 Jan;157:103127. doi: 10.1016/j.critrevonc.2020.103127. Epub 2020 Oct 21. PMID: 33161366.
Pediatric Wilson's Disease: Phenotypic, Genetic Characterization and Outcome of 182 Children in France.
Couchonnal E, Lion-François L, Guillaud O, Habes D, Debray D, Lamireau T, Broué P, Fabre A, Vanlemmens C, Sobesky R, Gottrand F, Bridoux-Henno L, Dumortier J, Belmalih A, Poujois A, Jacquemin E, Brunet AS, Bost M, Lachaux A.
J Pediatr Gastroenterol Nutr. 2021 Jun 1. doi: 10.1097/MPG.0000000000003196. Epub ahead of print. PMID: 34091542.
Peripheral Arrangement of Steatosis Microvacuoles in Wilson's Disease.
Laurent-Bellue A, Sobesky R, Guettier C.
Clin Gastroenterol Hepatol. 2021 Aug 5:S1542-3565(21)00839-9. doi: 10.1016/j.cgh.2021.08.005. Epub ahead of print. PMID: 34365001.
Pharmacological Premature Termination Codon Readthrough of ABCB11 in Bile Salt Export Pump Deficiency: An In Vitro Study.
Amzal R, Thébaut A, Lapalus M, Almes M, Grosse B, Mareux E, Collado-Hilly M, Davit-Spraul A, Bidou L, Namy O, Jacquemin E, Gonzales E.
Hepatology. 2021 Apr;73(4):1449-1463. doi: 10.1002/hep.31476. PMID: 32702170.
Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis.
Abergel A, Asselah T, Mallat A, Chanteranne B, Faure F, Larrey D, Gournay J, Loustaud-Ratti V, Di Martino V, Fouchard-Hubert I, Pol S, Bailly F, Samuel D, Tran A, Dodel M, Andant N, Lamblin G, Muti L, Reymond M, Teilhet C, Pereira B, Buchard B.
Liver Int. 2020 Aug;40(8):1853-1859. doi: 10.1111/liv.14502. Epub 2020 Jun 1. PMID: 32383275.
Portopulmonary hypertension in the current era of pulmonary hypertension management
Savale L, Guimas M, Ebstein N, Fertin M, Jevnikar M, Renard S, Horeau-Langlard D, Tromeur C, Chabanne C, Prevot G, Chaouat A, Moceri P, Artaud-Macari É, Degano B, Tresorier R, Boissin C, Bouvaist H, Simon AC, Riou M, Favrolt N, Palat S, Bourlier D, Magro P, Cottin V, Bergot E, Lamblin N, Jaïs X, Coilly A, Durand F, Francoz C, Conti F, Hervé P, Simonneau G, Montani D, Duclos-Vallée JC, Samuel D, Humbert M, De Groote P, Sitbon O.
J Hepatol. 2020 Jul;73(1):130-139. doi: 10.1016/j.jhep.2020.02.021. Epub 2020 Mar 5. Erratum in: J Hepatol. 2020 Nov;73(5):1293-1294. PMID: 32145258.
Post-Liver Transplantation Sinusoidal Obstruction Syndrome With Refractory Ascites Induced by Mycophenolate Mofetil.
Poli E, Kounis I, Guettier C, Verstuyft C, Coilly A, Sobesky R, Feray C, Vibert E, Ciacio O, Samuel D, Bismuth H, Duclos-Vallée JC.
Hepatology. 2020 Apr;71(4):1508-1510. doi: 10.1002/hep.30984. Epub 2020 Mar 31. PMID: 31597193
Pre-diagnostic alterations in circulating bile acid profiles in the development of hepatocellular carcinoma.
Stepien M, Lopez-Nogueroles M, Lahoz A, Kühn T, Perlemuter G, Voican C, Ciocan D, Boutron-Ruault MC, Jansen E, Viallon V, Leitzmann M, Tjønneland A, Severi G, Mancini FR, Dong C, Kaaks R, Fortner RT, Bergmann MM, Boeing H, Trichopoulou A, Karakatsani A, Peppa E, Palli D, Krogh V, Tumino R, Sacerdote C, Panico S, Bueno-de-Mesquita HB, Skeie G, Merino S, Ros RZ, Sánchez MJ, Amiano P, Huerta JM, Barricarte A, Sjöberg K, Ohlsson B, Nyström H, Werner M, Perez-Cornago A, Schmidt JA, Freisling H, Scalbert A, Weiderpass E, Christakoudi S, Gunter MJ, Jenab M.
Int J Cancer. 2021 Nov 29. doi: 10.1002/ijc.33885. Epub ahead of print. PMID: 34843121.
Predictive Factors for Hepatocellular Carcinoma in Chronic Hepatitis B Using Structural Equation Modeling: A Prospective Cohort Study.
Lam L, Fontaine H, Bourliere M, Lusivika-Nzinga C, Dorival C, Thabut D, Zoulim F, Habersetzer F, Asselah T, Duclos-Vallee JC, Bronowicki JP, Mathurin P, Decaens T, Ganne N, Guyader D, Leroy V, Rosa I, Ledinghen V, Cales P, Causse X, Larrey D, Chazouilleres O, Gelu-Simeon M, Loustaud-Ratti V, Metivier S, Alric L, Riachi G, Gournay J, Minello A, Tran A, Geist C, Abergel A, Raffi F, D'alteroche L, Portal I, Lapidus N, Pol S, Carrat F; ANRS AFEF Hepather study group.
Clin Res Hepatol Gastroenterol. 2021 Apr 27:101713. doi: 10.1016/j.clinre.2021.101713. Online ahead of print. PMID: 33930591
RAB10 Interacts with ABCB4 and Regulates Its Intracellular Traffic
Amel Ben Saad, Virginie Vauthier, Martine Lapalus, Elodie Mareux, Evangéline Bennana, Anne-Marie Durand-Schneider, Alix Bruneau, Jean-Louis Delaunay, Emmanuel Gonzales, Chantal Housset, Tounsia Aït-Slimane, François Guillonneau, Emmanuel Jacquemin, Thomas Falguières.
Int J Mol Sci. 2021 Jun 30;22(13):7087. doi: 10.3390/ijms22137087. PMID: 34209301.
Reply to: "Validation of the SURFASA score to define steroid responsiveness in patients with acute autoimmune hepatitis".
De Martin E, Duclos-Vallée JC.
J Hepatol. 2021 Nov 10:S0168-8278(21)02167-X. doi: 10.1016/j.jhep.2021.11.002. Epub ahead of print. PMID: 34774640.
Seronegative Autoimmune Hepatitis-Associated Severe Aplastic Anemia: Looking for the Best Treatment
Giuseppe Maggiore, Andrea Pietrobattista, Daniela Liccardo, Marco Sciveres, Silvia Nastasio, Emmanuel Jacquemin, Olivier Bernard.
J Pediatr Gastroenterol Nutr. 2021 May 11, PMID: 34016885, DOI: 10.1097/MPG.0000000000003165
Specific microbiome profile in Takayasu's arteritis and giant cell arteritis
Anne Claire Desbois, Dragos Ciocan, David Saadoun, Gabriel Perlemuter, Patrice Cacoub.
Sci Rep. 2021; 11: 5926.Published online 2021 Mar 15. doi: 10.1038/s41598-021-84725-5. PMID: 33723291. PMCID: PMC7961033
Systemic inflammation and liver cirrhosis complications: Driving or secondary event? How to square the circle?
Samuel D.
J Hepatol. 2021 Mar;74(3):508-510. doi: 10.1016/j.jhep.2021.01.001. Epub 2021 Jan 18. PMID: 33478857.
Ursodeoxycholic acid therapy throughout pregnancy in women affected with chronic cholestasis of childhood: No evidence for teratogenicity.
Lykavieris P, Bernard O, Jacquemin E.
Clin Res Hepatol Gastroenterol. 2021 May;45(3):101472. doi: 10.1016/j.clinre.2020.05.020. Epub 2020 Jun 18. PMID: 32565202.

A Model to Identify Heavy Drinkers at High Risk for Liver Disease Progression.
Claire Delacôte, Pierre Bauvin, Alexandre Louvet, Flavien Dautrecque, Line Carolle Ntandja Wandji, Guillaume Lassailly, Cosmin Voican, Gabriel Perlemuter, Sylvie Naveau, Philippe Mathurin, Sylvie Deuffic-Burban.
Clin Gastroenterol Hepatol. 2020 Sep;18(10):2315-2323.e6. doi: 10.1016/j.cgh.2019.12.041. Epub 2020 Jan 11.
A Novel CFC1 Mutation in a Family with Heterotaxy and Biliary Atresia Splenic Malformation Syndromes.
Gonzales E, Davit-Spraul A, Jacquemin E.
J Pediatr Gastroenterol Nutr. 2020;70:e24-e25.DOI: 10.1097/MPG.0000000000002531
Adenosine kinase deficiency: Three new cases and diagnostic value of hypermethioninemia.
Becker PH, Demir Z, Mozer Glassberg Y, Sevin C, Habes D, Imbard A, Mussini C, Rozenfeld Bar Lev M, Davit-Spraul A, Benoist JF, Thérond P, Slama A, Jacquemin E, Gonzales E*, Gaignard P*.
Mol Genet Metab. 2021:132:38-43.doi: 10.1016/j.ymgme.2020.11.007
Cardiovascular disorders in patients with congenital portosystemic shunts: 23 years of experience in a tertiary referral centre.
Lambert V, Ladarre D, Fortas F, Durand P, Hervé P, Gonzales E, Guérin F, Savale L, McLin VA, Ackermann O, Franchi-Abella S.
International Registry of Congenital Portosystemic Shunts (IRCPSS). Arch Cardiovasc Dis. 2020: Dec 3:S1875-2136(20)30237-0. doi: 10.1016/j.acvd.2020.10.003. Online ahead of print.
Diagnostic protocol of neonatal and infantile cholestasis: can it be improved?
Marco Sciveres, Francesco Cirillo, Emmanuel Jacquemin, Giuseppe Maggiore.
Comment J Pediatr. 2020 Jan;216:247. doi: 10.1016/j.jpeds.2019.09.045. Epub 2019 Oct 9.PMID: 31606154
Endoscopic Retrograde Cholangiopancreatography in infants: availability under threat: A survey on availability, need and clinical practice in Europe and Israel.
Koot BG, Kelly DA, Hadžić D, Gonzales E, Hierro L, Davenport M, Keil R, Fockens P, Baumann U.
J Pediatr Gastroenterol Nutr. 2020; 71(2):e54-e58.10.1097/MPG.0000000000002752.
Functional rescue of an ABCB11 mutant by ivacaftor: a new targeted pharmacotherapy approach in bile salt export pump deficiency.
Mareux E*, Lapalus M*, Amzal R, Almès M, Aït Slimane T, Delaunay JL, Adnot P, Collado-Hilly M, Davit Spraul A, Callebaut I, Gonzales E*, Jacquemin E*.
Liver Int. 2020;40:1917-1925.DOI: 10.1111/liv.14518
Geographical Disparities of Outcomes of Hepatocellular Carcinoma in France: The Heavier Burden of Alcohol Compared to Hepatitis C.
Charlotte E Costentin, Philippe Sogni, Bruno Falissard, Jean-Claude Barbare, NoelleBendersky, Olivier Farges, Nathalie Goutte.
Comparative Study Dig Dis Sci. 2020 Jan;65(1):301-311. doi: 10.1007/s10620-019-05724-1. Epub 2019 Jul 25.PMID: 31346950
Glycerol Phenylbutyrate Therapy in Progressive Familial Intrahepatic Cholestasis Type 2.
Almes M, Jobert A, Lapalus M, Mareux E, Gonzales E, Jacquemin E.
J Pediatr Gastroenterol Nutr 2020;70:e139-e140.10.1097/MPG.0000000000002713
Long term results of liver transplantation for alpha-1 antitrypsin deficiency.
Guillaud O, Jacquemin E, Couchonnal E, Vanlemmens C, Francoz C, Chouik Y, Conti F, Duvoux C, Hilleret MN, Kamar N, Houssel-Debry P, Neau-Cransac M, Pageaux GP, Gonzales E, Ackermann O, Gugenheim J, Lachaux A, Ruiz M, Radenne S, Debray D, Lacaille F, McLin V, Duclos-Vallée JC, Samuel D, Coilly A, Dumortier J.
Dig Liver Dis. 2020:S1590-8658(20)30970-1. doi: 10.1016/j.dld.2020.10.016. Online ahead of print.
Long-term results of pediatric liver transplantation for autoimmune liver disease.
Couchonnal E, Jacquemin E, Lachaux A, Ackermann O, Gonzales E, Lacaille F, Debray D, Boillot O, Guillaud O, Wildhaber BE, Chouik Y, McLin V, Dumortier J.
Clin Res Hepatol Gastroenterol. 2020 Oct 16:S2210-7401(20)30275-8. doi: 10.1016/j.clinre.2020.08.013. Online ahead of print.
Management of liver failure in general intensive care unit.
C Paugam-Burtz, E Levesque, A Louvet, D Thabut, R Amathieu, C Bureau, C Camus, G Chanques, S Faure, M Ferrandière, C Francoz, A Galbois, T Gustot, C Ichai, P Ichai, S Jaber, T Lescot, R Moreau, S Roullet, F Saliba, T Thévenot, L Velly, E Weiss.
Review Anaesth Crit Care Pain Med. 2020 Feb;39(1):143-161. doi: 10.1016/j.accpm.2019.06.014. Epub 2019 Sep 13.PMID: 31525507. DOI: 10.1016/j.accpm.2019.06.014
Optimization of the transition process of youth with liver disease in adulthood: A position paper from FILFOIE, the French network for paediatric and adult rare liver diseases.
Teresa Maria Antonini, Muriel Girard, Dalila Habes, Odile Goria, Dominique Debray.
Practice Guideline Clin Res Hepatol Gastroenterol. 2020 Apr;44(2):135-141. doi:10.1016/j.clinre.2019.07.018. Epub 2019 Sep 26.PMID: 31564624
Parvovirus B19 infection: A challenging cause of fulminant hepatitis.
Gille N, Roque-Afonso AM, Sebagh M, Rudler M, Thabut D, Duclos-Vallée JC, Samuel D, Coilly A.
Clin Res Hepatol Gastroenterol. 2020 Sep;44(4):e89-e91. doi: 10.1016/j.clinre.2019.12.004. Epub 2020 Jan 6. PMID: 31917176 No abstract available.
Pharmacological premature termination codon readthrough of ABCB11 in bile salt export pump deficiency: an in vitro study.
Amzal R, Thébaut A, Lapalus M, Almes M, Mareux E, Collado-Hilly M, Davit Spraul A, Bidou L, Namy O, Jacquemin E*, Gonzales E*.
Hepatology. 2020 Jul 23. doi: 10.1002/hep.31476.
Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis.
Armand Abergel, Tarik Asselah, Arianne Mallat, Brigitte Chanteranne, Frederic Faure, Dominique Larrey, Jerome Gournay, Veronique Loustaud-Ratti, Vincent Di Martino, Isabelle Fouchard-Hubert, Stanislas Pol, Francois Bailly, Didier Samuel, Albert Tran, Marie Dodel, Nicolas Andant, Geraldine Lamblin, Leon Muti, Maud Reymond, Camille Teilhet, Bruno Pereira, Benjamin Buchard.
Liver Int. 2020 Aug;40(8):1853-1859. doi: 10.1111/liv.14502. Epub 2020 Jun 1.PMID: 32383275
Plasma citrulline correlates with basolateral amino acid transporter LAT4 expression in human small intestine.
Stefano Maric, Pascal Flüchter, Laura Chiara Guglielmetti, Ralph Fabian Staerkle, Tom Sasse, Tanja Restin, Christoph Schneider, Stefan Gerhard Holland-Cunz, Pascal Crenn, Raphael Nicolas Vuille-dit-Bille*
Clinical Nutrition, https://doi.org/10.1016/j.clnu.2020.10.003
Portopulmonary hypertension in the current era of pulmonary hypertension management.
Savale L, Guimas M, Ebstein N, Fertin M, Jevnikar M, Renard S, Horeau-Langlard D, Tromeur C, Chabanne C, Prevot G, Chaouat A, Moceri P, Artaud-Macari É, Degano B, Tresorier R, Boissin C, Bouvaist H, Simon AC, Riou M, Favrolt N, Palat S, Bourlier D, Magro P, Cottin V, Bergot E, Lamblin N, Jaïs X, Coilly A, Durand F, Francoz C, Conti F, Hervé P, Simonneau G, Montani D, Duclos-Vallée JC, Samuel D, Humbert M, De Groote P, Sitbon O.
J Hepatol. 2020 Jul;73(1):130-139. doi: 10.1016/j.jhep.2020.02.021. Epub 2020 Mar 5.PMID: 32145258
Corrigendum to: "Portopulmonary hypertension in the current era of pulmonary hypertension management" [J Hepatol (2020);73:130-139].
Savale L, Guimas M, Ebstein N, Fertin M, Jevnikar M, Renard S, Horeau-Langlard D, Tromeur C, Chabanne C, Prevot G, Chaouat A, Moceri P, Artaud-Macari É, Degano B, Tresorier R, Boissin C, Bouvaist H, Simon AC, Riou M, Favrolt N, Palat S, Bourlier D, Magro P, Cottin V, Bergot E, Lamblin N, Jaïs X, Coilly A, Durand F, Francoz C, Conti F, Hervé P, Simonneau G, Montani D, Duclos-Vallée JC, Samuel D, Humbert M, De Groote P, Sitbon O.
J Hepatol. 2020 Nov;73(5):1293-1294. doi: 10.1016/j.jhep.2020.08.023. Epub 2020 Sep 7. PMID: 32907706 No abstract available.
Post-Liver Transplantation Sinusoidal Obstruction Syndrome With Refractory Ascites Induced by Mycophenolate Mofetil.
Poli E, Kounis I, Guettier C, Verstuyft C, Coilly A, Sobesky R, Feray C, Vibert E, Ciacio O, Samuel D, Bismuth H, Duclos-Vallée JC.
Hepatology. 2020 Apr;71(4):1508-1510. doi: 10.1002/hep.30984. Epub 2020 Mar 31. PMID: 31597193 No abstract available.
Reply to "Letter to the Editor: Post-Liver Transplantation Sinusoidal Obstruction Syndrome and immunosuppressive drugs: causality of MMF or tacrolimus?".
Poli E, Verstuyft C, Guettier C, Duclos Vallée JC.
Hepatology. 2020 Nov 17. doi: 10.1002/hep.31635. Online ahead of print. PMID: 33200416
Ursodeoxycholic acid therapy throughout pregnancy in women affected with chronic cholestasis of childhood: No evidence for teratogenicity.
Panayotis Lykavieris, Olivier Bernard, Emmanuel Jacquemin
Clin Res Hepatol Gastroenterol. 2020 Jun 18;101472. doi: 10.1016/j.clinre.2020.05.020. Online ahead of print.PMID: 32565202

Hépatinov develops innovative therapeutic
and diagnostic approaches for hepatic pathologies